{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T15:18:48Z","timestamp":1714490328567},"reference-count":27,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["mol clin onc"],"DOI":"10.3892\/mco.2018.1742","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T11:19:54Z","timestamp":1538738394000},"source":"Crossref","is-referenced-by-count":3,"title":["Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases"],"prefix":"10.3892","author":[{"given":"Tomonari","family":"Suetsugu","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Tanahashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi\ufffd","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"key20200713202129_b1-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20200713202129_b2-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"key20200713202129_b3-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20200713202129_b4-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1001\/jama.2010.1535","article-title":"Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab","volume":"304","author":"De Roock","year":"2010","journal-title":"JAMA"},{"key":"key20200713202129_b5-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20200713202129_b6-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"key20200713202129_b7-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"key":"key20200713202129_b8-mco-0-0-1742","article-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017","edition":"8th"},{"key":"key20200713202129_b9-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20200713202129_b10-mco-0-0-1742","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"key":"key20200713202129_b11-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20200713202129_b12-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1245\/s10434-006-9100-2","article-title":"Surgical management of pulmonary metastases from colorectal cancer in 153 patients","volume":"13","author":"Yedibela","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"key20200713202129_b13-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/SLA.0b013e31826eda3b","article-title":"Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: A retrospective analysis","volume":"257","author":"Iida","year":"2013","journal-title":"Ann Surg"},{"key":"key20200713202129_b14-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/jso.20926","article-title":"Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma","volume":"97","author":"Min","year":"2008","journal-title":"J Surg Oncol"},{"key":"key20200713202129_b15-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jso.21421","article-title":"Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph node metastasis below the level of renal vessels","volume":"101","author":"Choi","year":"2010","journal-title":"J Surg Oncol"},{"key":"key20200713202129_b16-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00384-017-2806-8","article-title":"Long-term outcomes after resection of para-aortic lymph node metastasis from left-sided colon and rectal cancer","volume":"32","author":"Nakai","year":"2017","journal-title":"Int J Colorectal Dis"},{"key":"key20200713202129_b17-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s11523-016-0445-6","article-title":"Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX plus cetuximab (JACCRO CC-05)","volume":"11","author":"Tsuji","year":"2016","journal-title":"Target Oncol"},{"key":"key20200713202129_b18-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgh.12847","article-title":"Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab","volume":"30","author":"Ye","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"key20200713202129_b19-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: A randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"key20200713202129_b20-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials","volume":"70","author":"Holch","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20200713202129_b21-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20200713202129_b22-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer","volume":"21","author":"Schwartzberg","year":"2014","journal-title":"Journal of clinical oncology: J Clin Oncol"},{"key":"key20200713202129_b23-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.ejso.2017.07.021","article-title":"The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection","volume":"43","author":"Poston","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"key20200713202129_b24-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/annonc\/mdv112","article-title":"Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: Results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann Oncol"},{"key":"key20200713202129_b25-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"e170278","DOI":"10.1001\/jamaoncol.2017.0278","article-title":"FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: A systematic review and pooled analysis","volume":"3","author":"Tomasello","year":"2017","journal-title":"JAMA Oncol"},{"key":"key20200713202129_b26-mco-0-0-1742","article-title":"NCCN: National Cancer Guidelines for Patients","volume-title":"Colon Cancer"},{"key":"key20200713202129_b27-mco-0-0-1742","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T10:32:02Z","timestamp":1662201122000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2018.1742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":27,"URL":"https:\/\/doi.org\/10.3892\/mco.2018.1742","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]}}}